Guizhou Bailing Group Pharmaceutical Co., Ltd.

Equities

002424

CNE100000PY3

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-16 pm EDT 5-day change 1st Jan Change
6.77 CNY +1.80% Intraday chart for Guizhou Bailing Group Pharmaceutical Co., Ltd. -9.37% -16.52%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024. CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Bailing Group Pharma Gets Green Light for Clinical Trial of New Hepatitis B Drug MT
China steel association says EU carbon tax a new trade barrier, calls for more talks RE
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
China’s Steel Consumption Falls 1.5% in January-September Period MT
China steel supply needs adjusting, industry official says RE
EU to launch first phase of world-first CO2 border tax RE
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023. CI
Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 9, 2023 has closed with 12,096,900 shares, representing 0.87% for CNY 100.01 million. CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023. CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. Announces Management Appointments CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023. CI
Zhejiang Futures Co., Ltd completed the acquisition of 11.17% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. from Jiang Wei. CI
Zhejiang Futures Co., Ltd agreed to acquire a 11.17% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. from Jiang Wei for approximately CNY 210 million. CI
GZ Bailing Buys Ownership of Traditional Chinese Drug for 20 Million Yuan; Shares Rose 3% MT
Guizhou Bailing Group Pharma to Repurchase Up to 200 Million Yuan Shares MT
Guizhou Bailing Group Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Zhang Shanlin completed the acquisition of 3.83% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. from Jiang Yong for approximately ¥500 million. CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chart Guizhou Bailing Group Pharmaceutical Co., Ltd.
More charts
GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of Chinese patent medicines. The Company is also engaged in the provision of Chinese medicine materials. The Company is also engaged in the distribution of fertilizers and purified water, and the operation of medical institutions. The Company conducts its businesses mainly within domestic markets.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.77
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002424 Stock
  4. News Guizhou Bailing Group Pharmaceutical Co., Ltd.
  5. Bailing Group Pharma Gets Green Light for Clinical Trial of New Hepatitis B Drug